Researchers in Germany followed 168 older patients with newly diagnosed multiple myeloma who were not eligible for stem cell transplant. The patients, with a median age of 77.7 years, received treatment with lenalidomide plus low-dose dexamethasone (Rd) in real-world clinical settings. The study aimed to see how this treatment worked outside of controlled clinical trials.
After a median follow-up of about 5 years, patients lived a median of 22.9 months without their disease worsening and a median of 58.1 months overall. Quality of life was maintained during treatment, and no new safety concerns emerged. Younger patients (75 years or less) and those without significant health impairments tended to have better outcomes.
This was a non-interventional, observational study that described what happened without testing specific hypotheses. The researchers analyzed data descriptively rather than making formal statistical comparisons. Real-world studies like this one show what happens in everyday practice but cannot prove that the treatment caused the outcomes.
Readers should understand this study supports Rd as a feasible treatment option for older multiple myeloma patients in real-world settings. However, the findings are descriptive and observational, meaning they show association rather than proof of effectiveness. Patients should discuss treatment options with their healthcare team based on individual circumstances.